Filing Flows › Comparisons › QDEL vs MYGN
QuidelOrtho vs Myriad Genetics: QDEL and MYGN compared
QuidelOrtho is the larger company: $619M of revenue in its latest quarter (Q3 2026) against $203M for Myriad Genetics (Q3 2026). Myriad Genetics is growing faster (-2% against -12% a year earlier). QuidelOrtho is more profitable, with an operating margin of -1.2% against -19.7%.
Where the money goes: QDEL and MYGN
QuidelOrtho (QDEL) · Q3 2026
QuidelOrtho, Q3 2026: revenue $619M (-12% year over year), operating margin -1.2%, net loss $53.8M, operating cash flow $19.6M. The chart follows the revenue to costs, profit and cash.
Myriad Genetics (MYGN) · Q3 2026
Myriad Genetics, Q3 2026: revenue $203M (-2% year over year), operating margin -19.7%, net loss $43.9M, operating cash flow −$6.5M. The chart follows the revenue to costs, profit and cash.
| QuidelOrtho (QDEL) | Myriad Genetics (MYGN) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $619M | $203M |
| Revenue growth, Y/Y | -12% | -2% |
| Operating margin | -1.2% | -19.7% |
| Net earnings | −$53.8M | −$43.9M |
| Net margin | -8.7% | -21.7% |
| Operating cash flow | $19.6M | −$6.5M |
| Free cash flow | $300K | — |
| Market value | $735M | — |
| Analysts’ mean target | $14.67 | — |
Where the revenue comes from
Myriad Genetics
- Cancer Care Continuum: $124M (61%)
- Mental Health: $39.5M (19%)
- Prenatal Health: $39.3M (19%)
Questions
Which is bigger, QuidelOrtho or Myriad Genetics?
QuidelOrtho is the larger company: $619M of revenue in its latest quarter (Q3 2026) against $203M for Myriad Genetics (Q3 2026).
Is QuidelOrtho or Myriad Genetics growing faster?
Myriad Genetics is growing faster (-2% against -12% a year earlier).
Which is more profitable, QuidelOrtho or Myriad Genetics?
QuidelOrtho is more profitable, with an operating margin of -1.2% against -19.7%.
More: QuidelOrtho earnings · how QuidelOrtho makes money · Myriad Genetics earnings · how Myriad Genetics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-Q filed Nov 6, 2026). Fiscal quarters can end on different dates. Not investment advice.